This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| acromegaly | |
|---|---|
| Name | Acromegaly |
| Field | Endocrinology |
| Symptoms | Enlarged hands and facial features, joint pain, sweating |
| Complications | Cardiovascular disease, diabetes mellitus, sleep apnea |
| Onset | Adulthood |
| Causes | Growth hormone–secreting pituitary adenoma |
| Diagnosis | Serum insulin-like growth factor 1, oral glucose tolerance test, pituitary MRI |
| Treatment | Surgery, medical therapy, radiotherapy |
| Frequency | Rare |
acromegaly Acromegaly is a chronic endocrine disorder caused by excessive growth hormone secretion in adulthood, typically from a pituitary adenoma, producing characteristic somatic and systemic effects. It leads to progressive soft tissue and bone enlargement, metabolic disturbances, and increased morbidity and mortality if untreated. Management involves multidisciplinary care spanning neurosurgery, endocrinology, cardiology, and sleep medicine, with ongoing surveillance for neoplastic and cardiovascular sequelae.
Patients usually present with insidious changes such as enlargement of the hands, feet, jaw, and nose, coarse facial features, and widening of interdental spacing. Common systemic manifestations include fatigue, arthralgia, carpal tunnel syndrome, and hyperhidrosis, often prompting referral to specialists including American Academy of Neurology, American College of Rheumatology, American Academy of Orthopaedic Surgeons, American College of Surgeons, Royal College of Physicians. Metabolic consequences include insulin resistance and overt diabetes mellitus, frequently managed in settings like Joslin Diabetes Center, Mayo Clinic, Mount Sinai Health System, Cleveland Clinic, Johns Hopkins Hospital. Cardiopulmonary signs include hypertension, cardiomyopathy, and obstructive sleep apnea, often requiring evaluation by American Heart Association, European Society of Cardiology, American Thoracic Society, British Thoracic Society, World Health Organization. Dermatologic and neurologic complaints—skin thickening, headaches, and visual field defects from optic chiasm compression—lead to involvement of centers such as Dermatology Institute of New York, Massachusetts General Hospital, Royal Brompton Hospital, Institute of Ophthalmology (UCL), Wills Eye Hospital.
The predominant cause is a benign somatotroph pituitary adenoma secreting excess growth hormone, often associated with aberrant somatic mutations or transcriptional dysregulation discovered in research at institutions like National Institutes of Health, Wellcome Trust Sanger Institute, Broad Institute, Cold Spring Harbor Laboratory, European Molecular Biology Laboratory. Less common causes include ectopic growth hormone–releasing hormone secretion from neuroendocrine tumors found at centers such as MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, UCSF Medical Center, Vanderbilt University Medical Center. Excess growth hormone increases hepatic insulin-like growth factor 1 production, affecting bone and soft tissue remodeling mediated through pathways elucidated by laboratories at Harvard Medical School, Stanford University School of Medicine, Yale School of Medicine, University of Cambridge, University of Oxford. Tumor mass effect explains headache and visual disturbance as described in classic neurosurgical series from Barrow Neurological Institute, Cleveland Clinic Foundation, Karolinska Institutet, UCLA Medical Center, Hopital Pitié-Salpêtrière.
Biochemical confirmation relies on elevated serum insulin-like growth factor 1 levels and failure of growth hormone suppression during a 75 g oral glucose tolerance test, protocols standardized by organizations such as Endocrine Society, European Society of Endocrinology, American Association of Clinical Endocrinologists, International Federation of Clinical Chemistry, World Health Organization. Magnetic resonance imaging of the sellar region identifies pituitary adenomas and is performed using scanners from manufacturers like GE Healthcare, Siemens Healthineers, Philips Healthcare, at imaging centers including Massachusetts General Hospital Radiology, Royal Marsden Hospital Radiology, John Radcliffe Hospital Radiology. Visual field testing by perimetry is arranged through ophthalmology services at Moorfields Eye Hospital, Bascom Palmer Eye Institute, Wills Eye Hospital, while cardiac evaluation often follows guidelines from European Society of Cardiology, American College of Cardiology, British Society for Heart Failure. Histopathologic confirmation and molecular profiling occur in pathology departments at Mayo Clinic Laboratories, Johns Hopkins Pathology, Royal College of Pathologists, guided by classifications from World Health Organization.
First-line therapy for most patients is transsphenoidal surgical resection performed by neurosurgeons at centers such as Cleveland Clinic, Johns Hopkins Hospital, Barrow Neurological Institute, Mount Sinai Hospital, UCLA Medical Center. Medical therapies include somatostatin analogues (octreotide, lanreotide) developed and marketed by pharmaceutical companies like Novartis, Ipsen, dopamine agonists such as cabergoline, and growth hormone receptor antagonists (pegvisomant) produced by firms including Pfizer, Eli Lilly and Company, Bristol-Myers Squibb; treatment algorithms follow guidance from the Endocrine Society and European Society of Endocrinology. Radiotherapy, including stereotactic radiosurgery delivered by teams at Gamma Knife Center (Karolinska), Cleveland Clinic Stereotactic Radiosurgery, UCSF Gamma Knife Center, is used when surgery and medication are insufficient. Multidisciplinary care frequently involves coordination between American Association of Neurological Surgeons, Endocrine Society, European Association of Neurosurgical Societies, Royal College of Surgeons.
Untreated disease increases risk of cardiovascular morbidity, including left ventricular hypertrophy and ischemic heart disease, with outcomes studied by American Heart Association, European Society of Cardiology, Framingham Heart Study, INTERHEART Study, Global Burden of Disease Study. Metabolic complications include type 2 diabetes and dyslipidemia managed following protocols from American Diabetes Association, International Diabetes Federation, Joint British Societies. Respiratory complications include obstructive sleep apnea with management by American Academy of Sleep Medicine, European Respiratory Society, National Sleep Foundation. Mortality trends have improved with modern therapies, as reported by registries and consortia such as European Registry of Cushing's and Acromegaly, Pituitary Society, International Pituitary Pathology Club, National Institutes of Health Clinical Center.
Acromegaly is rare, with prevalence estimates varying across cohorts and registries studied by Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, World Health Organization, National Institute for Health and Care Excellence, Scandinavian Pituitary Registry. Incidence and prevalence figures derive from population studies conducted in regions served by institutions like Karolinska Institutet, University of Helsinki, University of Texas Southwestern Medical Center, University of Sao Paulo, Seoul National University Hospital. Diagnostic delay is common, often resulting in referrals to tertiary centers such as Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Mount Sinai Hospital, Massachusetts General Hospital.
Descriptions of the disorder appear in clinical literature dating back to 19th-century European hospitals including Guy's Hospital, St Thomas' Hospital, Hospital de la Charité, Hôpital Lariboisière, Royal London Hospital. Historical cases drew attention from physicians associated with Royal Society, French Academy of Sciences, Royal College of Physicians, Royal College of Surgeons, and scholars at universities such as University of Edinburgh, University of Paris, University of Vienna, Heidelberg University, University of Bologna. Public awareness campaigns and patient advocacy are supported by organizations including Pituitary Foundation, Pituitary Network Association, European Pituitary Network, Hormone Health Network, Endocrine Society Patient Resources. High-profile legal, insurance, and disability considerations have involved institutions like Social Security Administration, National Health Service (England), Centers for Medicare & Medicaid Services, European Court of Human Rights, Supreme Court of the United States in cases addressing long-term care and access to specialty treatments.